Biogen Idec Inc. Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Jul 16 Calls Today's Calls

Call Details Biogen Idec Inc. Earnings Conference Call (Q2 2009) Thu, Jul 16, 2009, 8:30 am Eastern Listen to the archived event audio About Biogen Idec Inc. (NasdaqGS:BIIB) Other Calls  Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. The company’s marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkin’s Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb, a Phase III clinical trial product for the treatment of relapsed NHL; Anti-CD23 MAb, a Phase II/III clinical trial product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia; and ADENTRI, a Phase III clinical trial product for acute decompensated heart failure patients with renal insufficiency. The company’s products under preclinical stage comprise BIIB014, Daclizumab, CDP323, Humanized Anti-CD20 MAb, PEG-IFN beta 1a, Neublastin, and LINGO for neurology; Volociximab, Hsp90 Inhibitor, GA101, Anti-IGF-1R, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; BG-12, Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for autoimmune and inflammatory diseases; and ADENTRI and Aviptadil for cardiovascular diseases. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; mondoBIOTECH, AG; Alnylam Pharmaceuticals, Inc.; UCB, S.A.; Facet Biotech Corporation; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; and Schering AG, as well as a definitive agreement with AVEO Pharmaceuticals Inc. The company was founded in 1985 and is based in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings